Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
285
resultados
Última actualización
17/01/2026 [06:52:00]
Resumen de: US20260015411A1
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.
Resumen de: WO2026013203A1
The present invention relates to lipid nanoparticles (LNPs) comprising vitamin A or a vitamin A derivative. The LNPs according to the present invention show an improved stability and nucleic acid delivery efficacy.
Resumen de: US20260015406A1
The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.
Resumen de: US20260015315A1
An amino lipid compound, a preparation method therefor, a composition thereof and an application thereof. Specifically disclosed are an amino lipid compound represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a use thereof in preparing a lipid nanoparticle for delivering an active ingredient, and a composition containing the amino lipid compound, especially a lipid nanoparticle, and a use thereof.
Resumen de: US20260015236A1
An amorphous carbon has a three-dimensional arrangement of carbon nanoparticles as agglomerates and is produced from carbon-containing raw materials by a charring and distillation process. The carbon is suitable for medical use, as thermal and/or refractory and/or radiation-resistant insulating material, as a filter element, as a storage element or for the production of plant products or for planting water-poor regions. In another aspect, an electric energy storage device in the form of a double-layer capacitor has a symmetrical structure, with a housing and a collector each from the outside inwards, with an electrode formed as a carbon layer and a separator with an electrolyte, wherein the carbon layer is formed as agglomerates from an amorphous carbon produced by the method for the material treatment of carbon-containing raw materials and having the structure of the three dimensional arrangement of carbon nanoparticles.
Resumen de: US20260014259A1
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
Resumen de: US20260014251A1
Embodiments of the present disclosure provide novel compositions and methods for making and using thermostable polynucleotide-containing formulations. In certain embodiments, compositions and methods are disclosed for creating thermostable polynucleotides and/or thermostable polynucleotides encoding at least one therapeutic agent for use in therapies for the treatment of health conditions in a subject. In some embodiments, compositions and methods are disclosed for creating thermostable polynucleotides for use in therapeutics, vaccines, and targeted gene therapies. In other embodiments, compositions and methods are disclosed for creating thermostable polynucleotides capable of being coated or encased for prolonged storage and/or timed-delivery.
Resumen de: US20260014283A1
Provided herein are compositions comprising cells that each comprise at least one peptide-based nanoparticle. In some embodiments, the peptide-based nanoparticles each comprise a perfluorocarbon liquid core and a plurality of amphiphilic peptides surrounding the perfluorocarbon liquid core. Also provided herein are methods of preparing any of the compositions described herein, as well as methods of cellular tracking using any of the composition described herein.
Resumen de: US20260014278A1
The present invention relates to compositions that can deliver therapeutic molecules such as nucleic acids to mammalian cells, and to the human and animal body and methods of preparing and using the same. The compositions comprise nanoparticles comprising a peptide dendrimer, a nucleic acid and a lipid. The compositions of the invention find utility in the field of medicine, such as for treating cancer and autoimmune diseases.
Resumen de: US20260014281A1
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
Resumen de: US20260014124A1
Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
Resumen de: US20260014274A1
The present invention relates to compositions and methods for delivering nucleic acids into cells.
Resumen de: US20260014258A1
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
Resumen de: US20260014197A1
A drug delivery system including a zeolitic imidazolate framework-8 (ZIF-8), silica, platinum nanoparticles, and polyethylene glycol. The silica penetrates the pores of the ZIF-8 and at least partially envelopes the ZIF-8 to form a ZIF-8/silica composite. The platinum nanoparticles are present on the surface of the ZIF-8/silica composite, and the polyethylene glycol surrounds the platinum nanoparticles present on the surface of the ZIF-8/silica composite.
Resumen de: US20260014229A1
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Resumen de: US20260014090A1
Nanoparticles and formulations for non-surgical sterilization are disclosed herein. The nanoparticles for non-surgical sterilization contains a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agents can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivates the ovaries or testes. Uses for the nanoparticles and formulations incorporating the nanoparticles for sterilizing a subject in need thereof are also disclosed.
Resumen de: US20260014186A1
The invention relates to polymer nanoparticle and DNA nanostructure delivery compositions for non-viral delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticle delivery compositions, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, and DNA nanostructure delivery compositions, such as DNA origami compositions, for the delivery of more than one payload, or for the delivery of a nucleic acid construct payload of 3 kB or more, and methods therefor.
Resumen de: US20260014093A1
Embodiments of the present disclosure provide novel compositions and methods for making and using thermostable bacteriophage or bacteriophage-derived phage-like-particle (PLP)-containing formulations. In certain embodiments, compositions and methods are disclosed for embedding, decorating and/or associating at least one antigen or agent, or bioactive molecule on the surface of the bacteriophage or PLPs. In accordance with these embodiments, bacteriophage or PLPs harboring one or more antigen or agent, or bioactive molecule can further be thermostabilized and/or coated with one or more atomic layer deposition applied coating layer for control or timed release of the one or more antigen or agent when administered to a subject.
Resumen de: US20260014187A1
A composition includes a plurality of biocompatible metal nanospheres. the biocompatible nanospheres each having an outer surface with elemental carbon connected thereto. The composition also includes a plurality of single nucleic acids strands, wherein at least a portion of the respective individual single nucleic acid stands are in coordinated connection with the nanospheres, and a carrier medium.
Resumen de: US20260014094A1
A method is provided for producing a composition that includes a nanoparticle with at least one nucleic acid and at least one ionizable lipid. The method includes introducing a first composition that includes the at least one nucleic acid and a second composition that includes the at least one ionizable lipid into at least one reactor. The first composition and the second composition are introduced at a first flow rate and a second flow rate, respectively, therefore generating the nanoparticle in a reaction mixture. The method further includes filtering the nanoparticle from the reaction mixture via a single-pass tangential flow filter at a feed flux to provide a retentate, to produce the composition. The method may also include filtering the retentate through a sterile filtration membrane.
Resumen de: US20260014092A1
Provided are vaccines and immunomodulatory compositions containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo, that includes antigens and/or immunomodulatory proteins, nucleic acids, and nucleic acid encoding the proteins. The MEVs are formulated and administered by a variety of routes of administration that are advantageous for modulating the immune systems. Vaccines include those that are therapeutic for treating a disease, disorder, or condition, those that elicit an immunoprotective response, and/or otherwise modulate the immune system. The compositions include MEVs containing cargos for modulating intracellular receptors.
Resumen de: US20260014091A1
Disclosed herein are compositions and methods of making and use thereof. For example, disclosed herein are pharmaceutical compositions comprising: a plurality of redox-responsive disulfide nanoparticles; and a tyrosine kinase inhibitor encapsulated within each of the redox-responsive disulfide nanoparticles. Also disclosed herein are methods of treating or preventing an ocular injury, disease, or disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a plurality of redox-responsive disulfide nanoparticles and/or any of the pharmaceutical compositions disclosed herein to the subject.
Resumen de: US20260014089A1
The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.
Resumen de: US20260014175A1
A pharmaceutical composition in the form of a compressed tablet for oral administration. The composition has an intragranular portion including a first porous solid carrier with a physiologically acceptable salt that is soluble in gastric fluid/an acidic aqueous media, and a self-nanoemulsifying drug delivery system (SNEDDS) adsorbed on the carrier. The SNEDDS includes: at least one cannabinoid; one or more solubilizing agents selected from physiologically acceptable organic compounds including: alcohols C8-C18, cyclic alcohols, aromatic alcohols, glycerides, polyethylene glycols, polyethylene glycol esters, aromatic esters, phenols, tocopherols, phospholipids, polyoxylglycerides, or polyoxyethylene stearates; one or more emulsifying agents selected from physiologically acceptable nonionic surfactants; and one or more carrier oils. The composition has an extragranular portion including: an optional second porous solid carrier including a physiologically acceptable salt that is soluble in gastric fluid/an acidic aqueous media; one or more disintegrants; one or more diluents; and one or more lubricants.
Nº publicación: US20260014088A1 15/01/2026
Solicitante:
PANGEN BIOTECH INC [KR]
MOOGENE MEDI CO LTD [KR]
PANGEN BIOTECH INC,
MOOGENE MEDI CO., LTD
Resumen de: US20260014088A1
The present invention relates to lipid nanoparticles for the delivery of proteins and, specifically, to lipid nanoparticles for the intracellular or in vivo delivery of various medicinal proteins such as therapeutic proteins or enzymes for enzyme replacement therapy (ERT). The present invention can be advantageously used for the treatment and prevention of various diseases, including lysosomal storage disorders, by stably and effectively delivering various proteins such as therapeutic proteins or ERT enzymes into cells through lipid nanoparticles.
BOPI
Sede Electrónica
